September 2015:
A 71-year-old Caucasian male presented with severe left lower quadrant pain.
He sought medical treatment after experiencing bloody diarrhea.
PMH: hypertension, managed with benazepril.
He is active and can perform daily activities without restrictions.
Laboratory findings: remarkable for CEA, 6.0 ng/mL.
Colonoscopy showed a mass in the descending colon which was biopsied.
Pathological findings: Moderately differentiated adenocarcinoma.
NGS mutation testing results were NRAS, KRAS, HRAS, HER2, and BRAF wild-type.
Microsatellite stable.
CT of the chest, abdominal, and pelvis showed an 8-cm mass in the sigmoid colon.
a 2-cm mass in the right lobe of the liver, and a 5-cm in the left lobe adjacent to the left hepatic vein.
Impression: metastatic disease, borderline resectable.
Treatment was initiated with FOLFIRI + bevacizumab.
Imaging at 3 and 6 months showed decreased size of the liver nodules, but was not resectable.

July 2016:
The patient complained of increased fatigue, requiring the need for frequent rest.
CT scan showed increasing size of the liver nodule (3 cm) and appearance of 3 new small liver lesions (<2 cm).
He began therapy with FOLFOX + bevacizumab.

February 2017:
The patient reported weight loss, increasing fatigue, and shortness of breath.
CT scan revealed progressive disease with no improvement in the primary and metastatic lesion size and/or number.
A new pulmonary nodule was seen in the right lung.
He was switched to irinotecan + cetuximab.
PET/CT at 3 months showed stable disease.
At 6 months, he reported moderate improvement in fatigue.
